Lyonbiopole announces that the French Health authority (ANSM) delivered to Accinov, its Innovation Centre, the authorization to open a pharmaceutical site.

This authorization will allow Accinov to support the companies hosted in the Centre for the production of biological drugs for clinical trials in particular with the pharmaceutical responsibility of Accinov.

On September 11^th, the French Health authority (ANSM) delivered to Accinov the authorization to open a pharmaceutical site in its facilities located in Lyon-Gerland Biodistrict. This authorization followed an application submitted by Accinov to the ANSM and a favorable inspection completed on the site by the French Agency.

The authorization allows Accinov to provide companies involved in drug development programs with ready-to-use industrial facilities and pharmaceutical support services including quality assurance and batch release. Indeed, the ambition of Accinov is to ease and support the manufacturing of innovative biological drugs. Therefore, with this authorization, Accinov is now able to fulfill the needs of biopharmaceutical companies who want to start manufacturing GMP batches with a lot of flexibility and a full control of their know-how.

This authorization enables Accinov to achieve a new stage in the development of its unique biomanufacturing business model in Europe.

About Accinov

Accinov, the Innovation Centre of Lyonbiopole, opened in November 2013. The Centre provides biotechnology and biopharmaceutical companies with ready-to-use laboratories and biomanufacturing units dedicated to pharmaceutical production of biological drugs. These facilities are associated to quality assurance support services and pharmaceutical support services including pharmaceutical responsibility. Thus, Accinov enables GMP biomanufacturing, bio-analytical activities and other high value-added activities such as the manufacturing of medical devices.

The aim of the Centre is to allow companies developing their project as fast as possible. Indeed, Accinov empowers companies to control their process, their know-how and their intellectual property. This is possible by a range of infrastructure solutions and flexible services that enables compliance to quality requirements of the pharmaceutical industry (Good Manufacturing Practices, ISO...).

About Lyonbiopole

As a biocluster, Lyonbiopole is the one-stop shop for healthcare innovation in Rhône-Alpes, France. It aims to support the emergence and development of innovative technologies, products and services in  4 main strategic areas: human medicine, veterinary medicine, in vitro diagnostics, medical devices and medical technologies. Focused on infectious diseases since its creation in 2005, Lyonbiopole is now supporting ambitious projects and companies in other fields like cancer, nutrition, metabolic diseases and neurosciences. In 2013, Lyonbiopole represented a community of 139 members: 4 world-class leaders as Lyonbiopole’s founders (Sanofi Pasteur, bioMérieux, Merial, BD) – 19 Research Centers including 3 Hospital University Centers and almost 116 SMBs.

more about lyonbiopole